$EYPT

AstraZeneca (AZN) received FDA approval for Ultomiris in IgA nephropathy, with a 43.4% reduction in proteinuria. Merck (MRK) got EU approval for KEYTRUDA plus Padcev in bladder cancer, showing a 35% reduction in death risk. Alvotech (ALVO) approved a new manufacturing process for SIMLANDI. Cytokinetics (CYTK) won Health Canada approval for MYQORZO in obstructive HCM. Viatris (VTRS) approved RYZUMVI for presbyopia. Enlivex (ENLV) and EyePoint (EYPT) announced significant workforce reductions.

JPMorgan downgraded EyePoint Pharmaceuticals to 'Underweight' from 'Neutral' on October 20, 2026. The change reflects a reassessment of the company's valuation, EPS revisions, and visibility. EyePoint's stock has seen significant declines, including an 85.28% drop over the past year. The downgrade may impact investor sentiment and trading activity.

AstraZeneca (AZN) shares rose 1.8% premarket after Oracle (ORCL) announced a non-binding AI collaboration. Victoria’s Secret (VSXY) gained 1% following a Barclays price target increase to $112. EyePoint Pharmaceuticals (EYPT) fell 4.4% after JPMorgan downgraded it to 'Underweight' due to a clinical trial setback.

Amazon (AMZN) rose 4.98% after Morgan Stanley raised its price target to $350, citing AWS growth. Cleveland-Cliffs (CLF) gained 16.05% on Q3 earnings beat. Disc Medicine (IRON) surged 38.86% on positive trial results. Silence Therapeutics (SLN) soared 125.58% after Merck agreed to acquire it for $1.3B. EyePoint (EYPT) plunged 85.28% on trial failure and layoffs.

EyePoint, Inc.'s average stock price target was reduced from $22.33 to $20.89 by analysts, with a range of $1 to $48. This implies a 599% upside from the Oct. 16 closing price. The consensus rating remains 'Buy' among 13 analysts, with 5 Buys, 8 Holds, and 0 Sells.

EyePoint, Inc. (EYPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 EyePoint Announces Strategic Prioritization WATERTOWN, Mass., October 19, 2026 (GLOBE NEWSWIRE) – EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseas

EyePoint (EYPT) announced a strategic realignment after its Phase 3 LUCIA study for DURAVYU in wet AMD missed the primary endpoint. The company plans to cut 53% of jobs, saving $30M annually, and focus on DME trials. One-time charges are estimated at $9M. DME trial results are expected in Q4 2027.

EyePoint, Inc. (EYPT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU TM in Wet AMD – LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstra

Ocular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.

Arcturus Therapeutics (ARCT), MediciNova (MNOV), Inovio (INO), and Eyepoint Pharmaceuticals (EYPT) have upcoming binary events. ARCT has Phase II OTC-deficiency data and a Q4 cystic-fibrosis decision. MNOV expects Phase II data in September and COMBAT-ALS readout by year-end. INO awaits an FDA decision on INO-3107 in October. EYPT anticipates LUCIA Phase III data in Q4. All face significant binary risk.